POS5 THE COST-EFFECTIVENESS OF IBANDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN THE US
Earnshaw SR 1 , Graham CN 1 , Amonkar MM 2 , Barr CE 3 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 GlaxoSmithKline, Collegeville, PA, USA, 3 Roche Pharmaceuticals, Nutley, NJ, USA OBJECTIVES: We determined the cost-effectiveness of monthly ibandronate compared to weekly bisphosphonate (BP) treatments for women in the US, age ≥50 years, with prevalent radiologic vertebral deformity and hip BMD T-score ≤-2.5. METHODS: A Markov model was developed to evaluate the lifetime cost-effectiveness of monthly ibandronate and weekly BPs. Vertebral, hip, and wrist fracture efficacy were assigned a bisphosphonate class effect as estimated by the literature. Persistence with weekly BPs was evaluated at rates reported from observational studies (36% at year 1, 24% for years 2 through 5). Fifty-percent relative improvement in persistence (54% at year 1, 36% for years 2 through 5) among women receiving ibandronate was assumed based on previous improvements in persistence for weekly BPs. Both fracture risk and mortality were allowed to increase as patients aged. Yearly drug costs were referenced to wholesale acquisition costs for each BP. Direct health resource costs for fracture states were estimated from published literature and discounted 3% per annum. All costs were reported in 2004 US$. RESULTS: More fractures were avoided (vs. no treatment) with monthly ibandronate (94.13 per 1000 women) than with weekly BPs (57.57 per 1000 women), resulting in low lifetime fracture care costs/woman ($6726 and $6918, respectively). Five-year drug costs/patient were $1138 with weekly BPs and $1576 under conditions of improved persistence with monthly ibandronate. The incremental cost per quality-adjusted life year gained (vs. no treatment) was lower with monthly iban-dronate ($26,725) compared to weekly BPs ($31,601). Changing assumptions in the model to that of previously published cost-effectiveness models produced similar results, providing external validity for this model. CONCLUSION: Ibandronate is a cost-effective intervention for the treatment of postmenopausal osteoporosis. Incremental persistence with BP therapy thus improves the benefit realized in patient populations. These benefits include fewer fractures for patients without significant increases in costs to payers.
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COST OF FALLS IN LONG-TERM CARE FACILITIES (LTCFS)
Carroll NV 1 , Delafuente JC 1 , Cox FM 2 , Narayanan S 3 1 Virginia Commonwealth University, Richmond, VA, USA, 2 Pfizer, Inc, New York, NY, USA, 3 Beverly Enterprises, Fort Smith, AR, USA OBJECTIVE: To estimate the cost of falls in LTCFs.
METHODS:
The study employed a non-randomized, before and after comparison with control group design. A multi-facility long-term care company provided data from residents institutionalized between January 1, 2002 and October 30, 2004. Data included Minimum Data Set (MDS) observations, Resource Utilization Group (RUG) classifications, and demographics. An index date was assigned to each resident to identify pre-and postperiods. The index date was defined as the date of the first fall for fallers and as the date of the fifth MDS measurement for nonfallers. Direct medical cost estimates were based on MDS measures of hospital, emergency room, and physician utilization and on average Medicare reimbursement rates. Costs related to changes in resident functioning were estimated from RUG payment rates. Total reimbursement per resident per day (PRPD) was calculated as the sum of RUG and medical service reimbursements. Fall-related costs were estimated by comparing between-group differences in pre-to post-index period changes in reimbursement. Regression analysis was used to control for between-group differences. The dependent variable was the natural log of post-period total reimbursement. Independent variables included group, pre-period reimbursement, post-period length of stay, age, gender, race, and severity of illness as measured by a modified Charlson Comorbidity Index. RESULTS: The sample included 1298 fallers and 1509 non-fallers. Fallers had substantially more fractures and higher medical services utilization in the post-period than non-fallers. Total reimbursement for fallers decreased from $107 to $37 PRPD compared to a decrease from $98 to $24 for non-fallers. Regression analysis indicated that reimbursement in the post-period was 40% higher for fallers than non-fallers after controlling for demographic and disease differences and pre-period reimbursement. CONCLU-SION: Falls in LTCFs result in substantial costs, primarily due to higher hospitalization rates.
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CHANGES IN THE IMPAIRED ABILITY TO WORK IN PATIENTS UNDER 60 WITH MEDIAL FEMORAL NECK FRACTURE DURING 3 YEARS FOLLOW UP
Sebestyén A 1 , Boncz I 1 , Naumov I 2 , Nyárády J 2 1 National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2 University of Pécs, Pécs, Hungary OBJECTIVES: The aim of the study is to analyze on a 3 years follow up the 50-100% impaired ability to work related to medial fracture of femoral neck of patients in active age group regarding the surgical methods, the progressivity level of the primary treatment, rehabilitation care, age group and residence of patients, and the possible complications. METHODS: Data derive from the database of the National Health Insurance Fund Administration and based on the ICD-10 code S7200 (femoral
